Abstract
The presence of endometrial-like tissue outside the uterus cavity is the hallmark of endometriosis, a chronic, estrogen-dependent gynecological illness that lowers quality of life, causes discomfort, and impairs fertility in women of reproductive age. Hormonal therapy, analgesics, and surgical procedures are used to treat endometriosis; each of these treatments has the risk of adverse drug reactions (ADRs). Pharmacovigilance, which involves ongoing monitoring, ADR identification, and reporting, is essential to guaranteeing the safe and efficient use of these treatments. The underreporting of drug-induced side effects is still a significant problem in clinical practice, even with the abundance of available treatment alternatives. In order to enhance patient safety and therapeutic results, this article emphasizes the significance of pharmacovigilance in detecting, assessing, and averting negative effects associated with medications used to treat endometriosis.
Full text
1,235 characters
· extracted from
oa-doi-fallback
· click to expand
PHARMACOVIGILANCE PERSPECTIVE IN ENDOMETRIOSIS: A FOCUS ON SAFETY AND THERAPEUTICS MONITORING
Description
The presence of endometrial-like tissue outside the uterus cavity is the hallmark of endometriosis, a chronic, estrogen-dependent gynecological illness that lowers quality of life, causes discomfort, and impairs fertility in women of reproductive age. Hormonal therapy, analgesics, and surgical procedures are used to treat endometriosis; each of these treatments has the risk of adverse drug reactions (ADRs). Pharmacovigilance, which involves ongoing monitoring, ADR identification, and reporting, is essential to guaranteeing the safe and efficient use of these treatments. The underreporting of drug-induced side effects is still a significant problem in clinical practice, even with the abundance of available treatment alternatives. In order to enhance patient safety and therapeutic results, this article emphasizes the significance of pharmacovigilance in detecting, assessing, and averting negative effects associated with medications used to treat endometriosis.
Files
22 WJPR 38729.pdf
Files
(603.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:31589dcbc8e219ed8cc26f27554b2ec7
|
603.9 kB | Preview Download |
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.